Allogene Therapeutics Inc (ALLO)

Nov 20, 2024

Allogene stock touches 52-week low at $2 amid market challenges - Investing.com

Nov 20, 2024

Nov 20, 2024

Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN

Nov 20, 2024

Nov 19, 2024

ALLOAllogene Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 19, 2024

Nov 19, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewswire

Nov 19, 2024

Nov 19, 2024

Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan

Nov 18, 2024

Nov 18, 2024

Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com

Nov 18, 2024

Nov 18, 2024

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat

Nov 18, 2024

Nov 15, 2024

Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia

Nov 15, 2024

Nov 15, 2024

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™

Nov 15, 2024

Nov 14, 2024

Allogene halts enrollment in leukemia trial - Investing.com

Nov 14, 2024

Nov 14, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat

Nov 14, 2024

Nov 14, 2024

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace

Nov 14, 2024

Nov 14, 2024

Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat

Nov 14, 2024

Nov 14, 2024

Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK

Nov 14, 2024

Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024

Nov 12, 2024

Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India

Nov 12, 2024

Nov 10, 2024

Allogene Therapeutics Q3 2024 Earnings Preview - MSN

Nov 10, 2024

Nov 09, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Earnings call: Allogene Therapeutics reports on CAR T therapy progress - Investing.com

Nov 08, 2024

Nov 08, 2024

Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 08, 2024

Nov 08, 2024

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... - Yahoo Finance

Nov 08, 2024

Nov 08, 2024

Allogene Therapeutics: Q3 Earnings Snapshot - The Washington Post

Nov 08, 2024

Nov 07, 2024

Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Nov 07, 2024

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire

Nov 07, 2024

Nov 07, 2024

Allogene Therapeutics Announces Positive Phase 1 Data - GlobeNewswire

Nov 07, 2024

Nov 07, 2024

Allogene's Cancer Drug Shows 50% Response Rate in Phase 1 Trial, Earns FDA Designation | ALLO Stock News - StockTitan

Nov 07, 2024

Nov 06, 2024

Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Nov 06, 2024

Nov 05, 2024

Allogene Therapeutics to Present New Data Demonstrating the - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Allogene's ALLO-316 Cancer Therapy Shows Promise: Key Trial Data Coming at Major Symposiums | ALLO Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Allogene Therapeutics Inc - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.3%Still a Buy? - MarketBeat

Nov 04, 2024

Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024

Nov 04, 2024

Allogene Therapeutics Announces Participation in November Investor Conferences - StockTitan

Nov 04, 2024

Nov 02, 2024

Allogene Therapeutics’ (ALLO) “Buy” Rating Reiterated at HC Wainwright - Defense World

Nov 02, 2024

Oct 31, 2024

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance

Oct 31, 2024

Oct 31, 2024

Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 31, 2024

Allogene shares hold buy rating as FDA grants RMAT to ALLO-316 - Investing.com Australia

Oct 31, 2024

Oct 30, 2024

HC Wainwright Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat

Oct 30, 2024

Oct 30, 2024

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - The Manila Times

Oct 30, 2024

Oct 29, 2024

FDA grants RMAT status to Allogene's kidney cancer therapy By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

FDA grants RMAT status to Allogene's kidney cancer therapy - Investing.com

Oct 29, 2024

Oct 29, 2024

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) - The Manila Times

Oct 29, 2024

Oct 29, 2024

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance

Oct 29, 2024

Oct 29, 2024

Allogene Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire

Oct 29, 2024

Oct 29, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 29, 2024

Oct 28, 2024

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%Time to Buy? - MarketBeat

Oct 28, 2024

Oct 28, 2024

Allogene Therapeutics Inc (NASDAQ: ALLO) Stock Forecast: Could Pass $55 In A Year - Stocks Register

Oct 28, 2024

Oct 24, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 5.4%Should You Sell? - MarketBeat

Oct 24, 2024

Oct 24, 2024

Research Analysts Offer Predictions for ALLO Q3 Earnings - MarketBeat

Oct 24, 2024